Rich Ganz, MBA
Business Development Director
Mr. Ganz is a life sciences executive with over thirty years of experience in multinational pharma/device companies and venture-backed startups. He spent the first twenty years of his career at Abbott Laboratories, holding various positions in Sales, Marketing and General Management. His last position was Vice President and General Manager at Vascular Medicine. He joined Baxter Healthcare in 2001 as President, Renal North America. In 2004, he moved to Boston to join OmniSonics Medical Technologies as President and CEO. From 2012 to 2014, he was the Chief Operating Officer of Piramal Critical Care, a global leader in anesthetics. He has served on several private and one public company board of directors: Fresenius Kabi Pharmaceuticals Holding, Inc. He has also served on the following startup boards of directors: Sentien Biotechnologies (as chairman), Enefco, Forbes Consulting Group, Hypnalgesics, Hemametrics, First Light Biosciences. Rich has raised in excess of $40mm of new capital and has been involved in several successful exits:
- Hemametrics (Ganz served on the board of directors and was involved in its sales to Fresenius Medical Care in 2011).
- Enefco (Ganz served on the board of directors and was involved in the sale of the company to the private equity firm, Anvil Capital in 2012).
- Forbes Consulting Group (Ganz served on the board of the company and was involved in its sale to Copernicus in 2015).
He also has served as an executive in residence at the Cleveland Clinic and the University of Chicago. Mr. Ganz received his M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University and a Bachelor of Arts from the University of Minnesota.